Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

JACC Heart Failure(2021)10.1016/j.jchf.2021.06.018Source: DataRank Database

Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction is a research paper published in JACC Heart Failure (2021). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

47 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 5.26)OA: closedTopics (33)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Zhen Li ORCID,Melissa A. Greiner ORCID,Steven Lippmann ORCID,Stephen J. Greene ORCID,Robert J. Mentz ORCID

Live enrichment

PubMed:34509408 OpenAlex:https://openalex.org/W3197483280

American Heart Association

Abbott Laboratories

Boston Scientific Corporation

Novo Nordisk

Boehringer Ingelheim

National Institutes of Health

GlaxoSmithKline

Novartis

Amgen

AstraZeneca

Bayer

Bristol-Myers Squibb

Sanofi

Cytokinetics

Division of Advanced Cyberinfrastructure

Merck

Patient-Centered Outcomes Research Institute

Novartis Pharmaceuticals Corporation

FWCI

5.26

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S2213177921003358?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213177921003358?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jchf.2021.06.018

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34509408

Fields of Study

Heart Failure Treatment and ManagementMedication Adherence and ComplianceDiabetes Treatment and Management

MeSH Terms

ValsartanAftercareAgedAminobutyratesBiphenyl CompoundsDrug CombinationsMedicareHeart FailureHospitalizationHumansPatient DischargeStroke VolumeTetrazolesUnited StatesAngiotensin Receptor Antagonists

Keywords

Sacubitril, ValsartanMedicineValsartanEjection fractionSacubitrilHazard ratioHeart failureInternal medicineCardiologyConfidence intervalBlood pressureAdherenceHfrefArniSacubitril/valsartan

Sustainable Development Goals

SDG 0: Good health and well-being